tisagenlecleucel Archives - Medical Conferences

Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma

Presented By

Dr Michael Bishop, University of Chicago, IL, USA

Trial

Phase 3, BELINDA

Conference

ASH 2021

4 February, 2022 11:11

Axi-cel more effective but tisa-cel less toxic in DLBCL

Presented By

Dr Emmanuel Bachy, Hospices Civils de Lyon, France

Conference

ASH 2021

4 February, 2022 11:01

Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma

Expert

Dr Emmanuel Bachy, Hospices Civils de Lyon, France

Trial

JULIET, ZUMA-1

Conference

ASH 2021

4 February, 2022 10:15

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL

Expert

Dr Michael R. Bishop, David and Etta Jonas Center for Cellular Therapy, University of Chicago, USA

Trial

Phase 3, BELINDA

Conference

ASH 2021

4 February, 2022 10:03

CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients

Presented By

Dr Karl Kilgore, Avalere, USA

Conference

ASH 2019

5 March, 2020 21:07